Clinical trials: RANDOMIZED
Acquired Thrombotic Thrombocytopenic Purpura
Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
This study was a Phase II, single-blind, randomized, placebo-controlled trial to determine whether anti-vWF Nanobody is safe and effective as adjunctive treatment in patients with aTTP.
- Trial name
- TITAN (NCT01151423)
- Testing
- Caplacizumab
- Where
- 51 sites in United States, Australia and 11 more
- Volunteers
- 75 people
- Sponsor
- Ablynx, a Sanofi company
Irritable Bowel Syndrome, Diarrhea
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated, what side effects may occur, and the safety and efficacy in participants with Irritable Bowel Syndrome-Diarrhea (IBS-D).
- Trial name
- RENEW-IBS-D (NCT07545759)
- Testing
- LY3537031
- Where
- 89 sites in United States, Belgium and 8 more
- Volunteers
- 531 people
- Sponsor
- Eli Lilly and Company
Healthy
A Study to Learn About the Study Medicine Called PF-07054894 in People of Japanese Origin
The purpose of this clinical study is to learn about the safety and effects of the study medicine (PF-07054894) in healthy Japanese participants.
- Trial name
- NCT06327880
- Where
- Belgium
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pfizer
SARS-CoV-2
A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19
The primary goal for this study is to evaluate the safety and reactogenicity of 3 dose levels of mRNA-1283 and 1 dose level of mRNA-1273 vaccine given to healthy adults in 2 doses, 28 days apart, and 1 dose level of mRNA-1283…
- Trial name
- NCT04813796
- Testing
- mRNA-1283, mRNA-1273
- Where
- 5 sites in United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Breast Cancer
Nanogen Pegfilgrastim (Pegcyte) PK/PD Clinical Study in Breast Cancer Patients
Breast cancer patients scheduled to receive myelosuppressive chemotherapy (AC regimen) will be enrolled in this study. Eligible patients receive single SC injection of pegcyte or neulastim 24 hours after administration of…
- Trial name
- NCT03376503
- Testing
- Pegfilgrastim
- Where
- Vietnam
- Volunteers
- 24 people
- Sponsor
- Nanogen Pharmaceutical Biotechnology Joint Stock Company
Healthy
A First in Human Study to Assess the Safety, Tolerability and Immunogenicity of a Single Dose of a Trivalent Inactivated Poliovirus Vaccine Based on Sabin Strains (sIPV) Given Intramuscularly in Healthy Adults
The main purpose of this study is to assess the safety and tolerability of a single dose of JNJ-64152348, inactivated poliovirus vaccine produced from Sabin poliovirus strains on PER.C6 cells (sIPV) in healthy adults, using…
- Trial name
- NCT03032588
- Testing
- sIPV, cIPV
- Where
- Belgium
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Moderate to Severe Glabellar Lines
DWP450 for Treating Moderate to Severe Glabellar Lines
A multi-center, randomized, double-blind, positive drug-controlled clinical study to evaluate the safety and efficacy of Botulinum Toxin Type A for Injection in the treatment of moderate to severe glabellar lines
- Trial name
- NCT06354127
- Testing
- DWP450, Botox®
- Where
- China
- Volunteers
- 473 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Hepatic Impairment, Healthy Volunteers
Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects
The current study is proposed to evaluate whether there is any clinically meaningful effect of hepatic impairment on the plasma PK of PF-06865571.
- Trial name
- NCT04091061
- Testing
- PF-06865571 100 mg
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Telogen Effluvium
Efficacy and Safety of a Drinkable Nutraceutical for Hair Loss in Patients Using GLP-1/GIP Receptor Agonists
The purpose of this clinical trial is to evaluate the efficacy of Olistic© Next Women, a nutraceutical supplement, compared with placebo in improving hair loss in patients undergoing treatment with GLP-1/GIP agonists.
- Trial name
- NCT07484061
- Testing
- Drinkable multifactorial food supplement containing vitamins, minerals, amino acids, plant extracts, and other bioactive compounds, formulated to support hair growth and scalp health in women +45.
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Olistic Research Labs S.L.
Healthy
Study of NAV-240 in Healthy Volunteers
The primary purpose of this study is to evaluate the safety and tolerability of intravenous (IV) doses of NAV-240 in healthy volunteers.
- Trial name
- NCT06181786
- Testing
- NAV-240
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Navigator Medicines, Inc.
HIV-1-infection
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1
The goal of this clinical study is to learn about the safety and efficacy of switching to once weekly tablet of islatravir/lenacapavir (ISL/LEN) regimen versus continuing standard treatment of bictegravir/emtricitabine/tenofovir…
- Trial name
- ISLEND-1 (NCT06630286)
- Testing
- ISL/LEN, B/F/TAF, PTM B/F/TAF
- Where
- 106 sites in United States, Argentina and 10 more
- Volunteers
- 609 people
- Sponsor
- Gilead Sciences
Diabetes, Healthy
Comparison of Human Insulin Produced by the Current Process and the NN729 Process in Healthy Volunteers
This trial is conducted in Europe. The aim of this trial is to show that the product of the new production process has a similar pharmacological profile to the traditional process used for the current commercial product Actrapid®.
- Trial name
- NCT01448070
- Testing
- human insulin
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Bipolar I Depression
Lurasidone Pediatric Bipolar Study
A study to evaluate efficacy and safety of flexibly dosed Lurasidone in children and adolescents with bipolar I depression
- Trial name
- Illuminate (NCT02046369)
- Testing
- Lurasidone
- Where
- 66 sites in United States, Bulgaria and 9 more
- Volunteers
- 350 people
- Sponsor
- Sumitomo Pharma America, Inc.
Healthy
Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers
Crossover study to compare the pharmacokinetic characteristics of GLH1SM sustained release tablet and Janumet XR tablet in fasting condition
- Trial name
- NCT03851341
- Testing
- Janumet XR tablet 100/1000 mg, GLH1SM tablet 100/1000 mg
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GL Pharm Tech Corporation
Acne Vulgaris
Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris
This is a randomized, double-blind, multiple-site, placebo-controlled, parallel-group study, designed to compare the efficacy and safety of generic Clindamycin 1% gel (Akorn), and the marketed product Clindamycin 1% gel…
- Trial name
- NCT03522441
- Testing
- Clindamycin 1% Gel
- Where
- 12 sites in United States, Belize
- Volunteers
- 1,125 people
- Sponsor
- Akorn, Inc.
Lupus Erythematosus, Systemic
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE).
- Trial name
- TOPAZ-1 (NCT04895241)
- Testing
- Litifilimab
- Where
- 164 sites in United States, Australia and 13 more
- Volunteers
- 548 people
- Sponsor
- Biogen
Coronavirus Infections
A Study of Opaganib in Coronavirus Disease 2019 Pneumonia
This proof of concept study will take place in the US and other countries in approximately 15 clinical sites and will enroll about 40 hospitalized patients diagnosed with COVID-19 infection who have developed pneumonia and…
- Trial name
- COVID-19 (NCT04414618)
- Testing
- Opaganib
- Where
- 9 sites in United States, Israel
- Volunteers
- 42 people
- Sponsor
- RedHill Biopharma Limited
Relapsed/Refractory Multiple Myeloma
A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
This was a Phase 3, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of venetoclax plus bortezomib and dexamethasone in participants with relapsed or refractory multiple myeloma…
- Trial name
- Bellini (NCT02755597)
- Testing
- Venetoclax, Bortezomib, Dexamethasone
- Where
- 97 sites in United States, Australia and 14 more
- Volunteers
- 291 people
- Sponsor
- AbbVie
Benign Prostatic Hypertrophy (BPH)
A Clinical Trial to Evaluate the Effects of Food on the Bioavailability of CKD-397 in Healthy Male Subjects
This study is a randomized, open-label, oral single dosing, two-way crossover clinical trial to evaluate the effects of food on the bioavailability of CKD-397 after a single oral dose in healthy male subjects
- Trial name
- NCT02615782
- Testing
- CKD-397
- Where
- South Korea
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
COVID-19
A Bridging Study of FB2001 in Healthy Subjects
In the first human clinical trial conducted in the United States, single and multiple dosing of FB2001 in multiple dose groups were partially completed，and FB2001 demonstrated good safety and tolerability.
- Trial name
- NCT05197179
- Testing
- FB2001
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Frontier Biotechnologies Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.